-
EZ Cap™ Cas9 mRNA (m1Ψ): Assay Design
2026-08-26
EZ Cap™ Cas9 mRNA (m1Ψ) is a mRNA with Cap1 structure for transient CRISPR-Cas9 genome editing. This guide moves beyond formulation features to show how transcript handling, exposure kinetics, and nuclear-export biology can improve assay interpretation in mammalian cells.
-
EZ Cap Cy5 Firefly Luciferase mRNA: Uptake to Output
2026-08-26
Translational mRNA research increasingly needs to distinguish cellular uptake from productive cytosolic expression. This thought-leadership article examines how EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) enables dual-modality measurement, and how that framework can sharpen evaluation of emerging delivery systems such as redox-responsive peptide coacervates.
-
Fumagillin Against Azumiobodo hoyamushi: Study Review
2026-08-25
The reference study compared 20 antiprotozoal, antimicrobial, oxidizing, and halogen-based agents against Azumiobodo hoyamushi, the parasite associated with soft tunic syndrome in cultured ascidians. Fumagillin showed moderate in vitro activity, whereas formalin and chlorine dioxide produced the clearest reduction in parasite burden in experimentally infected animals, illustrating why in vitro potency must be validated in the host.
-
FK866 (APO866): NAD Metabolism Meets Immunity
2026-08-25
FK866 (APO866) is more than a potent NAMPT inhibitor: it is a strategic probe for understanding how NAD dependence shapes cancer vulnerability, mitochondrial stress, autophagy, and immune function. This article connects its established role in hematologic cancer research and acute myeloid leukemia treatment research with new insights from immune-adaptive pathogen variation, while outlining practical validation strategies and translational guardrails.
-
EZ Cap™ Cas9 mRNA (m1Ψ) Workflow Guide
2026-08-24
EZ Cap™ Cas9 mRNA (m1Ψ) combines Cap1 capping, m1Ψ modification, and a poly(A) tail for transient CRISPR-Cas9 experiments in mammalian cells. This practical guide connects RNA handling, delivery optimization, quantitative editing assays, and nuclear-export-based precision strategies.
-
Idoxuridine: Designing Translational Antiviral Assays
2026-08-24
Idoxuridine, also known as 5-iodo-2'-deoxyuridine, is a research-use nucleoside analog for investigating viral DNA synthesis inhibition. This article develops an evidence-calibrated assay strategy that connects orthogonal antiviral readouts with lessons from human-neuron translational pharmacology.
-
CORE LNPs Redirect mRNA Expression to the Spleen
2026-08-23
The CORE study introduces cholesterol-altered lipid nanoparticles designed to overcome the liver bias of systemic mRNA delivery and promote spleen-selective expression. By combining cholesterol-derivative synthesis, computational characterization, design-of-experiment optimization, and in vivo testing, the work provides a material-engineering strategy for spleen-directed vaccination and immune-modulation research.
-
CNQX: AMPA/Kainate Receptor Antagonist
2026-08-22
CNQX, also called 6-cyano-7-nitroquinoxaline-2,3-dione, is a competitive AMPA and kainate receptor antagonist for dissecting excitatory glutamatergic signaling. Its value as a neuroscience research tool depends on separating non-NMDA receptor blockade from NMDA-dependent mechanisms and controlling solvent, storage, and assay context.
-
ConA Targets Conserved Coronavirus Spike Glycans
2026-08-22
The reference study identifies two phylogenetically conserved, high-mannose N-glycans near the coronavirus spike S2′ cleavage site as a broad antiviral vulnerability. By combining fusion, pseudovirus, authentic-virus, biochemical, and animal models, the authors show that concanavalin A blocks spike activation and reduces hCoV-NL63 disease in mice.
-
Q-VD(OMe)-OPh in Apoptosis Assays
2026-08-21
Q-VD(OMe)-OPh provides a low-cytotoxicity way to separate caspase-dependent apoptosis from ferroptosis and autophagy in complex cell-death experiments. This guide translates its pan-caspase activity into practical workflows for resistant colorectal cancer models, differentiation studies, and neuroprotection research.
-
Influenza Hemagglutinin (HA) Peptide Workflow
2026-08-20
Use the HA tag peptide for selective, competition-based recovery of HA fusion proteins from immunoprecipitation workflows. Its high purity, broad solubility, and compatibility with interaction studies make it especially useful for testing RAB31-linked exosome biology without relying solely on harsh elution conditions.
-
Filipin III for Membrane Cholesterol Detection
2026-08-20
Filipin III is a cholesterol-binding polyene macrolide antibiotic used for cholesterol detection in membranes and membrane cholesterol visualization. Its fluorescence and membrane-perturbing behavior make it valuable for mapping cholesterol-rich membrane microdomains, but not a stand-alone quantitative cholesterol assay.
-
Tetrazolium (chloride): Read the Redox Signal
2026-08-19
Tetrazolium (chloride), also known as Tetrazolium Red or TTC, converts cellular reducing activity into a visible formazan signal. This guide explains how to interpret that signal across mitochondrial function assays, cell viability assays, and ischemic tissue studies without confusing metabolic competence with direct proof of survival.
-
Metoprolol: From Beta1 Blockade to Translation
2026-08-19
Metoprolol is more than a cardiovascular research reagent: it is a mechanistically interpretable probe for linking beta1-adrenergic signaling with inflammatory, tumor, and angiogenic biology. This thought-leadership article shows how pharmacokinetic context, disease-state modeling, and orthogonal readouts can turn beta1 blockade into a stronger translational research strategy.
-
GPX4, GSH, and Platinum Resistance in Brain Metastasis
2026-08-18
The reference study identifies a GPX4- and GSTM1-associated high-glutathione-consumption state as a driver of acquired platinum resistance in lung cancer-derived brain metastasis. Its integrated metabolic, proteomic, functional, and transcriptional analyses connect ferroptosis suppression to Wnt/NR2F2-dependent GPX4 upregulation, suggesting a mechanistic basis for combination strategies involving platinum drugs and GPX4 inhibition.